Teva stock surged early Wednesday after the drugmaker reported adjusted earnings of 78 cents per share on $4.48 billion in third-quarter sales. On average, analysts polled by FactSet expected Teva Pharmaceutical (TEVA) to earn 68 cents per share on $4.38 billion in sales. During the year-earlier period, Teva reported earnings of 69 cents per share and $4.33 billion in sales. Teva hiked its guidance for Austedo. The company now expects the movement disorders drug to bring in $2.05 billion to $2.15 billion in ...

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio. ...

周三，梯瓦制药(TEVA.US)盘前大涨近13%，报23.10美元。梯瓦制药Q3营收为44.8亿美元，市场预期为 43.4亿美元；调整后每股收益0.78美元，市场预期为0.68美元。公司预计2025财年全年收入区间为168亿 美元至170亿美元，而FactSet的预估为168.3亿美元。公司将2025财年调整后每股收益指引从2.50-2.60美 元上调至2.55-2.65美元，分析师预期为2.58美元。 ...

智通财经APP获悉，周三，梯瓦制药(TEVA.US)盘前大涨近13%，报23.10美元。梯瓦制药Q3营收为44.8 亿美元，市场预期为43.4亿美元；调整后每股收益0.78美元，市场预期为0.68美元。公司预计2025财年 全年收入区间为168亿美元至170亿美元，而FactSet的预估为168.3亿美元。公司将2025财年调整后每股 收益指引从2.50-2.60美元上调至2.55-2.65美元，分析师预期为2.58美元。 ...

Teva Pharmaceutical Industries (NYSE:TEVA) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Speaker1Hello and welcome to the Q3 2025 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I'll be coordinating today's call. If you'd like to ask a question at the end of the presentation, please press star followed by one on your telephone keypad. I'll now hand it over to Chris Stevo, SVP, Investor Relations. Please go ahead.Speaker2Thank you, Alex. Good morning and good afternoon, ev ...

November 5, 2025 Teva Pharmaceutical Industries Ltd. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statem ...

公司财务表现 - 第三季度利润增长超出预期 [1] - 业绩受到三款品牌药强劲销售的推动 [1] 产品销售情况 - 三款品牌药分别用于治疗偏头痛、亨廷顿病等 [1]

EXHIBIT 99.1 Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe se ...

For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment decreased by 10% in LC, or increased by 2% in LC excluding Japan BV in Q3 2024, all ...

Wall Street analysts expect Teva Pharmaceutical Industries Ltd. (TEVA) to post quarterly earnings of $0.68 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues are expected to be $4.35 billion, up 0.4% from the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.4% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the c ...